§Appl. No. 09/646,924 Amdt. dated June 8, 2005 Reply to Office Action of, December 15, 2004

Listing of Claims:

Please amend the claims as follows:

Listing of Claims:

Claim 1 (Currently Amended) A method of screening a substance for usefulness in the treatment of a lipid metabolism dysfunction comprising contacting said substance with a RORa receptor, or a response element of human RORa located at position 198 to +24 of the human apo C-III promoter involved in the regulation of the apo C-III gene, and measuring the level of apo C-III gene expression or the level of expression of a reporter gene placed under the control of a promoter comprising said response element.

Claim 3 (Cancelled)
Claim 4 (Cancelled)
Claim 5 (Cancelled)
Claim 6 (Cancelled)
Claim 7 (Cancelled)

(Cancelled)

Claim 2

Claim 8 (Cancelled)

Claim 9 (Cancelled)

Claim 10 (Currently Amended) The method of screening according to claim 19, wherein the reporter gene is chosen from chloramphenical acetyltransferase, the gene for luciferase from firefly or from Renilla, the gene for secreted alakaline phosphatase, the gene for beta-galactosidase or the gene for apo C-III.

Claim 11 (Cancelled)

§Appl. No. 09/646,924 Amdt. dated June 8, 2005 Reply to Office Action of, December 15, 2004

Claim 12 (Currently Amended) The method of screening according to claim 13, wherein the effect of said substance on the expression of said apo C-III or reporter gene is determined using transfection or analysis of mRNAs *in vitro* or on models *in vitro* or *in vivo*.

Claim 13	(Cancelled)
Claim 14	(Cancelled)
Claim 15	(Cancelled)
Claim 16	(Cancelled)
Claim 17	(Cancelled)
Claim 18	(Cancelled)
Claim 19	(Cancelled)
Claim 20	(Cancelled)
Claim 21	(Cancelled)

Claim 22 (Currently Amended) A method of measuring the expression of the apo C-III gene, comprising contacting a substance with a ROR α receptor or a response element of the ROR α receptor located at position—198 to +24 of the apo C-III promoter or a nuclear factor which couples ROR α to a RNA polymerase complex, and then measuring:

i) the binding of said substance to the ROR α receptor or the binding of the complex formed by the said substance and the ROR α receptor to the response element or to a nuclear factor which couples ROR α to a RNA polymerase complex;

or

ii) the modulation of the transcriptional activity of a gene placed under the control of a promoter comprising said response element.

§Appl. No. 09/646,924 Amdt. dated June 8, 2005 Reply to Office Action of, December 15, 2004

Claim 23 (Cancelled)

Claim 24 (Cancelled)

Claim 25 (Currently Amended) A method of screening a substance for usefulness in the treatment of a lipid metabolism dysfunction comprising,

contacting said substance with a RORa receptor, and a response element of RORa located at position 198 to +24 of the apo C-III promoter involved in the regulation of the apo C-III gene, and and measuring the binding of said receptor to said response element.

Claim 26 (Previously Presented) A method of claim 25, wherein the measuring is performed by the gel retardation method.

Claim 27 (Cancelled)

Claim 28 (Cancelled)

Claim 29 (Cancelled)

Claim 30 (Cancelled)

Claim 31 (New) A method of claim 1, wherein the level of apo C-III gene expression is measured.

Claim 32 (New) A method of claim 1, wherein the level of a reporter gene expression is measured.